NCT03345134 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03345134
Title	Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Shaheen Alanee
Indications	renal pelvis transitional cell carcinoma ureter transitional cell carcinoma
Therapies	BCG solution + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 1 of 1 entries

Facility	Status	City	State	Zip	Country	Details
Shaheen Alanee, MD, MPH, MBA		Detroit	Michigan	48202	United States	Details

Showing 1 to 1 of 1 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03345134Clinical Trial Detail